1.
The clinical and cost effectiveness of epoetin alfa before orthopedic surgery in patients with mild anemia
Craig J, Brown H, Eastgate J, Macpherson K, Wilson S
Transfusion Alternatives in Transfusion Medicine. 2008;10((Suppl 1):):44. Abstract No. P68.
2.
Two years budget impact of epoetin alfa and autologous blood donation to avoid allogeneic transfusion in patients undergoing hip or knee orthopedic major surgery, from a major hospital perspective
Gomez-Barrera M, Izuel-Rami M, Garcia-Erce JA, Mendaza M, Rabanaque MJ
Transfusion Alternatives in Transfusion Medicine. 2006;8((1s):):79. Abstract No. P51.
3.
Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery
van Hulst M, Bilgin YM, van de Watering LM, de Vries R, van Oers MH, Brand A, Postma MJ
Transfusion Medicine. 2005;15((3):):209-17.
Abstract
Cost-effectiveness of leucodepleted erythrocytes (LD) over buffy-coat-depleted packed cells (PC) is estimated from the primary dataset of a recently reported randomized clinical trial involving valve surgery (+/-CABG) patients. Data on the patient level of 474 adult patients who were randomized double-blind to LD or PC were used in order to calculate the healthcare costs and longevity per patient. The incremental cost-effectiveness ratio (ICER) in net costs per life-year gained was established from the healthcare perspective. Bootstrapping and cost-effectiveness acceptability curves were used in order to determine the confidence interval (CI) of the ICER. The longevity of patients in the PC and LD group was 10.6 and 11.4 years, respectively. Relative to PC, LD yielded an estimated 0.8 (95% CI = -0.27 to 1.84) life-year in the baseline. Adjusted for age and sex differences, health gains for LD are 0.4 life-year gained (95% CI = -0.67 to 1.44). Healthcare costs per patient averaged 10163 US dollars per patient in the PC group and 9949 US dollars in the LD group. Average cost-savings were 214 US dollars (95% CI = -1536 to 1964) per patient. Acceptability curves constructed from bootstrap simulations showed a probability of being cost-saving of 59% for universal leucodepletion from the healthcare perspective. The probability of adopting leucodepletion regardless of the costs reaches 92.7%. LD in patients receiving four or more transfusions showed the highest cost-savings and health gains. Leucodepletion of erythrocytes is a cost-saving strategy in cardiac valve (+/-CABG) patients. However, probablistic analysis failed to show a significant difference with buffy-coat-depleted PC.
4.
Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery
Coyle D, Lee KM, Fergusson DA, Laupacis A
Pharmacoeconomics. 2000;18((2):):161-71.
5.
Maintaining intraoperative normothermia: a meta-analysis of outcomes with costs
Mahoney CB, Odom J
AANA Journal. 1999;67((2):):155-63.
6.
Economic analysis of erythropoietin use in orthopaedic surgery
Coyle D, Lee KM, Fergusson DA, Laupacis A
Transfusion Medicine. 1999;9((1):):21-30.
7.
Economic evaluations of technologies to minimize perioperative transfusion: a systematic review of published studies
Fergusson D, van Walraven C, Coyle D, Laupacis A, International Study of Peri-operative Transfusion investigators
Transfusion Medicine Reviews. 1999;13((2):):106-17.
